吉西他滨联合卡铂治疗复发性上皮性卵巢癌临床分析

Clinical analysis of Gemcitabine and Carboplatin in treatment of recurrent epithelial ovarian cancer

目的探讨吉西他滨(Gem)联合卡铂治疗复发性上皮性卵巢癌的有效性和不良反应。方法采用随机对照研究的方法,将2008-08-2010-12间在川北医学院附属医院收治的48例复发性上皮性卵巢癌患者随机分为研究组(Gem联合卡铂)和对照组(紫杉醇联合卡铂),对其疗效及不良反应进行比较。结果对照组和研究组完全缓解率(CR)分别为12.5%和29.17%,总有效率分别为45.83%和79.17%,不良反应分别提高54.17%和25.00%。研究组CR和总有效率明显高于对照组(P<0.01),研究组治疗后不良反应明显低于对照组(P<0.01)。结论 Gem联合卡铂治疗复发性上皮性卵巢癌的临床疗效较好,不良反应较低。

Objective To investigate the therapeutic effects and adverse effects of Gemeitabine and Carboplatin in treatment of recurrent epithelial ovarian cancer.Methods The controlled study for the randomized cases was performed in 48 patients with recurrent epithelial ovarian cancer in our department between Aug 2008 and Dec 2010.The patients were divided randomly into study group（24 cases） and control group（24 ases）.Study group received the treatment of Gemeitabine and Carboplatin.Control group received the treatment of Paclitaxel and Carboplatin.The therapeutic effect and adverse effect were analyzed.Results Complete remission（CR） of control group and study group was 12.5% and 33.33% respectively.The total effective rate of control group and study group was 45.83% and 79.17% respectively.Adverse effect of control group and study group was 54.17% and 25% respectively.CR and total effective rate of study group were obvious more than those of control group（P0.01）.Adverse effect of study group was obvious lower than that of control group（P0.01）.Conclusion Therapeutic effect is higher and adverse effect is lower for gemeitabine combined carboplatin in treatment of recurrent epithelial ovarian cancer.